Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Genomic Urine Testing Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The genomic urine testing market size has seen rapid expansion in recent years. Its value is expected to rise from $1.01 billion in 2025 to $1.13 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. The historical growth experienced in this sector is due to advancements in molecular diagnostics, the demand for non-invasive testing, initial biomarker research, the adoption of genomic assays by laboratories, and the overall growth in oncology diagnostics.
The genomic urine testing market is projected to experience swift expansion in the coming years. By 2030, its value is anticipated to reach $1.8 billion, demonstrating a compound annual growth rate (CAGR) of 12.2%. Key factors driving this growth during the forecast period include the integration of such testing with routine health screenings, its expanded application in detecting infectious diseases, advancements in technological sensitivity, the increasing need for personalized monitoring, and robust clinical validation studies. Significant trends expected in this period encompass the growing acceptance of non-invasive diagnostic tests, the increased application of genomic biomarkers for disease identification, a heightened demand for tools for early cancer screening, the broadening of personalized diagnostic methods, and intensified research into urinary genomic profiling.
Get A Free Sample Report With In-Depth Market Insights:
Genomic Urine Testing Market Growth Catalysts And Demand Drivers
The rising prevalence of chronic kidney disease is projected to drive the expansion of the genomic urine testing market in the future. Chronic kidney disease (CKD) is defined as a state where kidneys are impaired, rendering them unable to efficiently filter blood, resulting in the accumulation of waste products and fluids within the body. The increasing incidence of diabetes contributes to the growing burden of CKD, given that elevated blood sugar levels harm renal blood vessels, thereby compromising their waste-filtering capacity. Genomic urine testing assists in managing chronic kidney disease through its capacity for early identification of genetic markers, facilitating prompt interventions and tailored treatment strategies. This testing improves patient results by allowing for more precise monitoring and slowing the advancement of the disease. For example, in November 2025, The American Journal of Managed Care, a US-based peer-reviewed medical publication, reported that 788 million adults aged 20 and older were living with CKD in 2023. Consequently, the escalating burden of chronic kidney disease fuels the expansion of the genomic urine testing market.
Genomic Urine Testing Market Segment Analysis And Revenue Potential
The genomic urine testing market covered in this report is segmented –
1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing
2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies
3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis
2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection
3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis
4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing
Genomic Urine Testing Market Industry Trends: What’s Reshaping Demand?
Leading companies active in the genomic urine testing market are prioritizing the development of innovative solutions, such as next-generation sequencing, to enhance the precision, sensitivity, and early detection capabilities of non-invasive diagnostic tests for various diseases. Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables the rapid, accurate, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, launched the genomic urine test UroAmp. This test utilizes next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes associated with bladder cancer, allowing for early detection up to 12 years before clinical symptoms emerge. It provides detailed genetic insights to assist with diagnosis, treatment decisions, and recurrence monitoring, offering higher accuracy than traditional methods like cytology and cystoscopy.
Genomic Urine Testing Market Key Players Shaping Industry Direction
Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd
View The Full Genomic Urine Testing Market Report:
Genomic Urine Testing Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
